MDA

MDA

MDA

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

This is a commonly used substance with well known and widely available human consumption data. This does not guarantee that the substance will be safe. The safety profile has been established based on usage data commonly available.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

MDA

Also known as:

  • 3,4-Methylenedioxyamphetamine[Wiki]
  • (±)-3,4-(Methylenedioxy)amphetamine
  • (±)-3,4-Methylenedioxyamphetamine
  • (R,S)-3,4-Methylenedioxyamphetamine
  • 1-(1,3-Benzodioxol-5-yl)-2-propanamin[German][ACD/IUPAC Name]
  • 1-(1,3-Benzodioxol-5-yl)-2-propanamine[ACD/IUPAC Name]
  • 1-(1,3-Benzodioxol-5-yl)-2-propanamine[French][ACD/IUPAC Name]
  • 1-(1,3-benzodioxol-5-yl)propan-2-amine
  • 1-(3,4-Methylenedioxyphenyl)-2-aminopropane
  • 1,3-Benzodioxole-5-ethanamine, α-methyl-[ACD/Index Name]
  • 3,4-Methylenedioxy-a-methyl-b-phenylethylamine
  • 3,4-methylenedioxy-α-methyl-β-phenylethylamine
  • 5-(2-Aminopropyl)-1,3-benzodioxole
  • a-Methyl-1,3-benzodioxole-5-ethanamine
  • MDA
  • MFCD00867901[MDL number]
  • Phenethylamine, α-methyl-3,4-(methylenedioxy)-
  • Phenethylamine, α-methyl-3,4-(methylenedioxy)-
  • Phenethylamine, α-methyl-3,4-(methylenedioxy)-, (±)-
  • Tenamfetamina[Spanish]
  • ténamfétamine[French][INN]
  • TENAMFETAMINE, (R)-
  • TENAMFETAMINE, (S)-
  • Tenamfetaminum[Latin][INN]
  • tenamphetamine
  • tenanfetamina[Spanish][INN]
  • α-Methyl-3,4-methylenedioxyphenethylamine
  • тенамфетамин[Russian][INN]
  • 替苯丙胺[Chinese][INN]
  • (±)2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine
  • (±)-3,4-METHYLENEDIOXYAMPHETAMINE-D5
  • (±)-α-Methyl-1,3-benzodioxole-5-ethanamine
  • (±)-α-Methyl-3,4-(methylenedioxy)phenethylamine
  • (RS)-3,4-(methylenedioxy)methamphetamine
  • 1-(1,3-Benzodioxol-5-yl)-N-methyl-2-propanamine[ACD/IUPAC Name]
  • 1-(1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine
  • 1-(2H-1,3-benzodioxol-5-yl)propan-2-amine
  • 1-(3,4-Methylenedioxyphenyl)-2-propylamine
  • 1,3-Benzodioxole,5-ethanamine-α-methyl-(±)
  • 1,3-Benzodioxole-5-ethanamine, α-methyl-
  • 1-[3, 4-(Methylenedioxy)phenyl]-2-aminopropane
  • 2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine
  • 3,4-Methylenedioxy-amphetamine
  • 3,4-Methylenedioxymethamphetamine[Wiki]
  • DL-(3,4-Methylenedioxy)methamphetamine
  • MDA HYDROCHLORIDE
  • Methylenedioxyamphetamine
  • N,α-dimethyl-1,3-benzodioxole-5-ethanamine
  • N-Methyl-3,4-methylenedioxyamphetamine
  • rac-3,4-Methylenedioxyamphetamine
  • rac-MDA
  • α-Methyl-1,3-benzodioxole-5-ethanamine
  • α-Methyl-3,4-(methylenedioxy)phenethylamine
  • α-Methyl-3,4-(methylenedioxy)phenethylamine
  • α-Methyl-3,4-methylenedioxyphenethylamine
  • (-)2-Benzo[1,3]dioxol-5-yl-1-methyl-ethylamine

A stimulant and empathogen. Similar to MDMA but typically produces more visuals than MDMA. Known to be more neurotoxic than MDMA, and is a minor metabolite of MDMA. Duration and onset similar to MDMA. The common Marquis reagent test cannot differentiate MDA and MDMA.

Summary

It produces long-lived entactogenic, stimulant and mild psychedelic effects that include stimulation, anxiety suppression, enhanced feelings of empathy, affection, and sociability, and euphoria when administered. MDA was first synthesized in 1910 but its psychoactive effects were not discovered until in 1930. It was used in animal and human trials between 1939 and 1941 and from 1949 to 1957.

More than 500 human subjects were given MDA in an investigation of its potential use as either an antidepressant or anorectic. By 1958, it was successfully patented as a cough suppresant and ataractic. By 1961 it was patented as an anorectic under the trade name “Amphedoxamine”.

Contemporary reports suggest that MDA emerged as a recreational drug towards the end of 1967, meaning its use predates its more widely used relative MDMA (Ecstasy). As with MDMA, MDA is thought to act primarily as a serotonin-norepinephrine-dopamine reuptake inhibitor and releasing agent. However, MDA is significantly more potent by weight and subjective intensity relative to MDMA.

It also has a notably longer duration (six to eight hours instead of three to five) and produces more traditional serotonergic psychedelic effects (such as visual distortions) along with appreciably higher activity on dopamine, which is also believed to be responsible for the greater degree of neurotoxicity it produces. Today, possession of MDA is illegal in most countries, although some limited exceptions exist for scientific and medical research.

History

Mannish and W. Jacobson in 1910. However, its psychoactive effects were not discovered until the self-experiments of Gordon Alles in July 1930.

Alles would later license the drug to Smith, Kline & French. The first animal tests occurred in 1939, followed by human trials in 1941 that explored it as a possible therapy for Parkinson’s disease. From 1949 to 1957, more than 500 human subjects were given MDA in an investigation of its potential use as an antidepressant and anorectic by Smith, Kline & French. The United States Army also experimented with the drug, code-named EA-1298, while working to develop a truth drug or incapacitating agent.

A man named Harold Blauer died in January 1953 after being intravenously injected with 450 mg of the drug. MDA was eventually patented as a cough suppressant by H. D. Brown in 1958, as an ataractic by Smith, Kline & French in 1960, and as an anorectic under the trade name “Amphedoxamine” in 1961.

MDA began to appear on the recreational drug scene around 1967. In early 1968, the Bureau of Drug Abuse Control reported the seizure of over 1.4 kilograms of MDA and 11 kilograms of precursors from a clandestine laboratory in New York. Several researchers, including Claudio Naranjo and Richard Yensen, have explored utilizing MDA in the field of psychotherapy. In 2010, Matthew Baggott and colleagues studied the ability of MDA to invoke mystical experiences and alter vision in healthy volunteers.

Chemistry

MDA

MDA

Molecules of the amphetamine class contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα.

MDA also contains substitutions at R3 and R4 of the phenyl ring with oxygen groups.

These oxygen groups are incorporated into a methylenedioxy ring through a methylene chain.

MDA shares this methylenedioxy ring with MDMA, MDAI and more obscure variants like MDEA or MMDA.

Common Name3,4-Methylenedioxyamphetamine
Systematic name3,4-Methylenedioxyamphetamine
FormulaC_{10}H_{13}NO_{2}
SMILESCC(Cc1ccc2c(c1)OCO2)N
Std. InChiInChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3
Std. InChiKeyNGBBVGZWCFBOGO-UHFFFAOYSA-N
Avg. Mass179.2157 Da
Molecular Weight179.2157
Monoisotopic Mass179.094635 Da
Nominal Mass179
ChemSpider ID1555

Subscribe for the latest updates

Dosing Guide

Oral
Light30-40mg
Common40-80mg
Strong80-120mg
Heavy120mg+

Duration

MDA Duration Data
Onset20-90 minutes
Duration2-5 hours
After-effects1-12 hours

Interactions and Synergies

Caution

  1. Mushrooms
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  2. LSD
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  3. DMT
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  4. Mescaline
    • The focus and anxiety caused by stimulants is magnified by psychedelics and results in an increased risk of thought loops
  5. 2C-x
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally uneccessary because of the stimulating effects of psychedelics. Combination of the stimulating effects may be uncomfortable.
  6. Cannabis
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  7. Ketamine
    • No unexpected interactions, though likely to increase blood pressure but not an issue with sensible doses. Moving around on high doses of this combination may be ill advised due to risk of physical injury.
  8. MXE
    • Risk of tachycardia, hypertension, and manic states
  9. Cocaine
    • This combination of stimulants will increase strain on the heart. It is not generally worth it as cocaine has a mild blocking effect on dopamine releasers like amphetamine
  10. Caffeine
    • This combination of stimulants is not generally necessary and may increase strain on the heart, as well as potentially causing anxiety and greater physical discomfort.
  11. Alcohol
    • Drinking on stimulants is risky because the sedative effects of the alcohol are reduced, and these are what the body uses to gauge drunkenness. This typically leads to excessive drinking with greatly reduced inhibitions, high risk of liver damage and increased dehydration. They will also allow you to drink past a point where you might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less. Extended release formulations may severely impede sleep, further worsening the hangover.
  12. GHB/GBL
    • Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
  13. Opioids
    • Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.

Dangerous

  1. DOx
    • The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of amphetamine can easily lead to thought loops. Coming down from amphetamines while the DOx is still active can be quite anxiogenic.
  2. NBOMes
    • Amphetamines and NBOMes both provide considerable stimulation. When combined they can result in tachycardia, hypertension, vasoconstriction and in extreme cases heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
  3. 2C-T-x
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences. In extreme cases, they can result in severe vasoconstriction, tachycardia, hypertension, and in extreme cases heart failure.
  4. 5-MeO-xxT
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
  5. DXM
    • Both substances raise heart rate, in extreme cases, panic attacks caused by these drugs have led to more serious heart issues.
  6. PCP
    • This combination can easily lead to hypermanic states

Low Synergy

  1. Benzodiazepines
    • Both can dull each other's effects, so if one wears off before the other it's possible to overdose due to the lack of counteraction

No Synergy

  1. SSRIs

High Synergy

  1. N2O
  2. MDMA
    • Amphetamines increase the neurotoxic effects of MDMA

General Information

Experiences
Oral
Vaporization
Come up
Dosage
Effects
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test ResultBlack
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

MDA acts as a releasing agent and reuptake inhibitor of the neurotransmitters known as serotonin, dopamine and norepinephrine. It also functions as a 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist and shows affinity for the TAAR1, α2A-, α2B-, α2C-adrenergic receptors and 5-HT1A and 5-HT7 receptors. The effect on serotonin may explain the similar euphoric and empathogenic effects of the two compounds MDMA and MDA. However, MDA has a higher efficacy in stimulating the 5-HT2A receptor than MDMA; thus MDA tends to cause more psychedelic-like effects, such as visual geometry and hallucinations. While MDMA can also produce psychedelic-like visual effects, these are less pronounced than those of MDA or require a heavier dose to become apparent. It is worth noting that the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective Effects

While MDA is similar to MDMA, users report that MDA has more stimulant and psychedelic qualities and less intense entactogenic effects than MDMA. MDA is also considered to be less predictable than MDMA, with effects varying greatly from person to person.

Physical Effects

  • Stimulation & Sedation - In terms of its effects on the user's physical energy levels, MDA is commonly considered to have the paradoxical ability to both be stimulating as well as sedating and relaxing. While MDA is described as being more "speedy" than MDMA, as attributed of its higher dopamine transporter affinity. it can also produce a pronounced sedating stoning or couch-locking effect depending on one's set and setting. Unlike MDMA, this can both discourage or encourage activities such as group socializing and dancing in a way that makes it a popular substance for musical events such as festivals and raves.
  • Spontaneous physical sensations - The "body high" of MDA can be described as a moderate to extreme euphoric tingling sensation that radiates throughout the entire body. It is capable of becoming overwhelmingly pleasurable at higher doses and capable of immobilizing the user. This sensation maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
    • Physical euphoria - The physical euphoria MDA has been noted to produce is often described as intensely pleasurable and all-encompassing at its peak.
  • Tactile enhancement - One may find surfaces such as rugs, carpets, blankets, or skin to be softer and more pleasant to the touch while under the influence of this subject's effects.
  • Bodily control enhancement
  • Vibrating vision - At high doses, a person's eyeballs may begin to spontaneously wiggle back and forth in a rapid motion, causing the vision to become blurry and temporarily out of focus. This is a condition known as nystagmus.
  • Temperature regulation suppression
    • Increased bodily temperature - As MDA is a serotonin releasing agent, a rise in core body and brain temperature tends to be high and consistent throughout the experience. Caution must be taken as too high of a dose can result in the dysregulation of the brain's ability to regulate its internal core temperature, which can result in serotonin syndrome, a condition which can be fatal if left untreated.
  • Increased blood pressure
  • Increased heart rate
  • Increased perspiration
  • Dehydration - Feelings of dry mouth and dehydration are a universal experience with this class of compounds; this effect is a product of an increased heart rate and metabolism. While it is important to avoid becoming dehydrated (especially when out dancing in a hot environment), there have been some notable cases of users suffering from water intoxication through over-drinking (to compensate). It is therefore advised that users simply sip on their water and avoid over-drinking.
  • Difficulty urinating - Higher doses of MDA result in an overall difficulty when it comes to urination. This is an effect that is completely temporary and harmless. It is due to MDA’s promotion of the release of anti-diuretic hormone (ADH); ADH is responsible for regulating urination. This effect can be lessened by simply relaxing, but can be significantly relieved by placing a hot flannel over the genitals to warm them up and encourage blood flow to the region.
  • Appetite suppression
  • Pupil dilation
  • Excessive yawning
  • Stamina enhancement
  • Teeth grinding - This is usually only present at moderate to higher doses and is similar to what one might experience from MDMA.
  • Temporary erectile dysfunction
  • Seizure - This is a rare effect but can happen in people predisposed to them, especially when taking heavier-than-recommended doses or while in physically taxing conditions, such as being dehydrated, fatigued or undernourished.

Psychological Effects

The cognitive effects of MDA can be broken down into several components which progressively intensify proportional to dosage. The headspace of MDA is described by many as one of moderate to extreme mental stimulation, feelings of love, openness or empathy, and powerful euphoria. It displays a large number of typical psychedelic, entactogenic and stimulant cognitive effects. The most prominent of these cognitive effects generally include:

Visual Effects

The visual effects of MDA have an occurrence rating that is more selective and less consistent than any of the traditional psychedelics. The effects can never be guaranteed to manifest themselves, but are the most likely to occur with chemically pure, high dose MDA experiences, towards the end of the experience and particularly if the user has been smoking cannabis. They are also more likely to occur if the user has prior experience with psychedelics, but also remain entirely possible for those who have never tried them as well. Unlike MDMA, MDA can directly induce mild to moderate psychedelic visual effects due to its ability to partially agonize the 5HT2A receptor, which means it has the ability to induce moderate psychedelic visual effects.

Enhancements

MDA presents an array of visual enhancements which are mild in comparison to traditional psychedelics, but still distinctively present. These generally include:

Distortions

Geometry

The visual geometry that is present throughout this experience can be described as more similar in appearance to that of psilocin than LSD. It can be comprehensively described through its variations as primarily intricate in complexity, abstract in form, organic in style, structured in organization, dimly lit in lighting, mostly monotone in colour with blues and greys, glossy in shading, sharp in edges, small in size, fast in speed, smooth in motion, equal in round and angular corners, non-immersive in-depth and consistent in intensity. At higher doses, they are significantly more likely to result in states of level 8A visual geometry over level 8B.

Hallucinatory states

At high to heavy doses, MDA is capable of producing a unique range of low and high-level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics. These effects are far more common during the offset of the experience and commonly include:

  • Peripheral information misinterpretation
  • Transformations
  • External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very similar to the same experience found within deliriants, but does not manifest itself consistently and usually happens only at high doses. It can be comprehensively described through its variations as delirious in believability, autonomous in controllability and solid in style. They usually follow themes of memory replays and semi-realistic or expected events. For example, people could be casually holding objects or performing actions which one would expect them to be in real life before disappearing and dissolving under further inspection. Common examples of this include seeing people wearing glasses or hats when they are not and mistaking faces of friends for random people, and objects as human beings or animals.
  • Internal hallucination - The internal hallucinations which MDA induce are mostly only present as spontaneous breakthroughs at extremely high doses. This effect's variations are delirious in believability, interactive in style, new experiences in content, autonomous in controllability and solid in appearance. The most common way in which they manifest themselves is through hypnagogic scenarios which the user may experience as they are drifting off to sleep after a night of use; these can usually be described as memory replay from the previous several hours. These are short and fleeting, but frequent and completely believable and convincing as they happen. In terms of the theme, they often take the form of conversations with the people who were with you or instead manifest themselves as bizarre and extremely nonsensical plots.

Auditory Effects

Sensory Effects

Transpersonal Effects

  • Existential self-realization - Although this effect is present, it is not quite as pronounced or as consistent when compared to other hallucinogens such as mescaline, LSD or MXE. Due to the relative calmness and lack of chaotic energy that MDA possesses relative to MDMA, however, this combined with its extended duration may make it a better therapeutic agent and can be thought of as being more similar to mescaline than MDMA.
  • Unity and interconnectedness - Experiences of unity, oneness, and interconnectedness between level 2 - 3 are common within MDA. This component most consistently manifests itself at high doses within large crowds at raves and musical events in the form of "becoming one with the crowd."

Legal Status

Internationally, MDA is part of the the Convention on Psychotropic Substances of 1971 as a Schedule I substance.

  • Australia: MDA is a controlled substance.
  • Austria: MDA is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
  • Canada: MDA is listed on the CSDA in Schedule I.
  • Germany: MDA is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of September 1, 1984. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
  • Russia: MDA is classed as a Schedule I prohibited substance.
  • Switzerland: Possession, production and sale is illegal.
  • The Netherlands: MDMA is illegal to possess, produce and sell in the Netherlands
  • United Kingdom: MDA is a class A drug.
  • United States: MDA is a Schedule I drug.

  • References

    1. Über Oxyphenyl-alkylamine und Dioxyphenyl-alkylamine | http://onlinelibrary.wiley.com/doi/10.1002/cber.19100430126/abstract;jsessionid=CF00D19D5BF8D9E4343735C6B27E57AE.f03t03
    2. Schoenfeld, Eugene. "Hippocrates". Berkeley Barb November 24-30, 1967: 7 (Independent Voices) | http://voices.revealdigital.com/cgi-bin/independentvoices?a=d&d=BFBJFGD19671124.1.7
    3. Über Oxyphenyl-alkylamine und Dioxyphenyl-alkylamine | http://onlinelibrary.wiley.com/doi/10.1002/cber.19100430126/abstract;jsessionid=CF00D19D5BF8D9E4343735C6B27E57AE.f03t03
    4. "Methylenedioxy Amphetamine (MDA)." Microgram. Bureau of Drug Abuse Control. Feb 1968. 1(5):4-5 (Erowid.org) | https://erowid.org/library/periodicals/microgram/microgram_1968_02_v01n05.pdf
    5. Evaluation of 3,4-Methylenedioxyamphetamine (MDA) as an Adjunct to Psychotherapy | http://www.karger.com/Article/Abstract/137100
    6. MDA-assisted psychotherapy with neurotic outpatients: a pilot study (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/972325
    7. Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0014074
    8. Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/22037049
    9. Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/18805646
    10. Serotonin-dopamine Interaction: Experimental Evidence and Therapeutic Relevance | http://books.google.com/books?id=mPkKtA15KM8C&pg=PA294
    11. Serotonergic drugs and valvular heart disease (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/19505264
    12. Effect of the R(-) and S( ) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/7824160
    13. Psychedelics and the human receptorome (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20126400
    14. Johnson, M. P., Hoffman, A. J., & Nichols, D. E. (1986). Effects of enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. European Journal of Pharmacology, 132(2–3), 269–276. https://doi.org/10.1016/0014-2999(86)90615-1
    15. The History Channel documented details of his death here http://www.youtube.com/watch?v=ySw-0uY4CUA See minute 2:38 onward.
    16. http://www.drogen-info-berlin.de/htm/mda.html
    17. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089
    18. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
    19. "CONVENTION ON PSYCHOTROPIC SUBSTANCES 1971" (PDF). United Nations. Retrieved December 15, 2019.
    20. "Criminal Code Regulations 2019". Office of Parliamentary Counsel. Retrieved December 15, 2019.
    21. "Controlled Drugs and Substances Act - SCHEDULE I". Government of Canada. Retrieved December 15, 2019.
    22. "Erste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 15, 2019.
    23. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 15, 2019.
    24. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 15, 2019.
    25. Resolution of the Government of the Russian Federation | https://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=314201&fld=134&dst=100034,0&rnd=0.41568319511755825#047741519652799347
    26. Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien | https://www.admin.ch/opc/de/classified-compilation/20101220/index.html
    27. https://wetten.overheid.nl/BWBR0001941/2020-01-01

    Resources

    1. 1717 CheMall HE005817
    2. 1717 CheMall HE097341
    3. ACToR: Aggregated Computational Toxicology Resource 4764-17-4
    4. Advanced Technology & Industrial 3570867
    5. AKos AKOS022196424
    6. American Custom Chemicals Corp CHM0016492
    7. American Custom Chemicals Corp RDL0007345
    8. Aurora Fine Chemicals A01.300.747
    9. Aurora Fine Chemicals K02.574.997
    10. BIND (no longer updated) 320
    11. ChemAdvisor OHS14933
    12. ChemAdvisor OHS30310
    13. ChemBank DivK1c_000964
    14. ChemBank KBio1_000964
    15. ChemBank NINDS_000964
    16. ChEMBL CHEMBL6731
    17. ChemDB 3964846
    18. ChemIDplus 004764174
    19. ChemIDplus 051497097
    20. ChemIDplus 4764174
    21. ChemIDplus 51497097
    22. ChemIDplus 61614606
    23. ChemIDplus 65620668
    24. Chemspace CSC000065886
    25. Collaborative Drug Discovery 2
    26. CSDeposition Service DB01509
    27. DiscoveryGate 1614
    28. DrugBank DB01509
    29. DTP/NCI 27106
    30. DTP/NCI 9978
    31. eMolecules 591812
    32. Erowid MDA
    33. FDA UNII - NLM UNII: XJZ28FJ27W
    34. FDA UNII - NLM XJZ28FJ27W
    35. Finetech Industry FT-0694584
    36. Human Metabolome Database HMDB0041931
    37. Human Metabolome Database HMDB41931
    38. LabNetwork LN01299555
    39. Laboratory Chemical Safety Summary 1614
    40. LeadScope LS-103643
    41. LeadScope LS-103644
    42. LGC Standards LGCAMP1360.05-01
    43. MassBank EQ371501
    44. MassBank EQ371502
    45. MassBank EQ371503
    46. MassBank EQ371504
    47. MassBank EQ371505
    48. MassBank EQ371506
    49. MassBank EQ371507
    50. MassBank EQ371508
    51. MassBank EQ371509
    52. MassBank WA000401
    53. MassBank WA000402
    54. MassBank WA000403
    55. MassBank WA000404
    56. MassBank WA000405
    57. MassBank WA000406
    58. Mcule MCULE-6462457769
    59. NIST Chemistry WebBook 3231091281
    60. NIST Chemistry WebBook 594204764
    61. NIST Spectra mainlib_352965
    62. NIST Spectra nist ri
    63. NIST Spectra replib_125758
    64. NIST Spectra replib_248177
    65. NIST Spectra replib_250570
    66. NIST Spectra replib_313160
    67. NIST Spectra replib_335530
    68. PubChem 1614
    69. PubMed 10080646
    70. PubMed 10080649
    71. PubMed 10381769
    72. PubMed 10388483
    73. PubMed 10517560
    74. PubMed 10654563
    75. PubMed 10670737
    76. PubMed 10671903
    77. PubMed 10675019
    78. PubMed 10720721
    79. PubMed 10782961
    80. PubMed 10928627
    81. PubMed 10975633
    82. PubMed 11027867
    83. PubMed 11106329
    84. PubMed 11110193
    85. PubMed 11129070
    86. PubMed 11209252
    87. PubMed 11225861
    88. PubMed 11232860
    89. PubMed 11276966
    90. PubMed 11300514
    91. PubMed 1133132
    92. PubMed 11386639
    93. PubMed 11394297
    94. PubMed 11473798
    95. PubMed 11550823
    96. PubMed 11568088
    97. PubMed 11718314
    98. PubMed 11763093
    99. PubMed 1178673
    100. PubMed 11897967
    101. PubMed 11900801
    102. PubMed 11909652
    103. PubMed 11924548
    104. PubMed 11948818
    105. PubMed 11991532
    106. PubMed 12062939
    107. PubMed 12134820
    108. PubMed 12146919
    109. PubMed 12166811
    110. PubMed 12185492
    111. PubMed 12231444
    112. PubMed 12498266
    113. PubMed 1255447
    114. PubMed 12569443
    115. PubMed 12587677
    116. PubMed 12592588
    117. PubMed 12658701
    118. PubMed 12670001
    119. PubMed 12714929
    120. PubMed 12726843
    121. PubMed 12761331
    122. PubMed 12782103
    123. PubMed 12860031
    124. PubMed 12906896
    125. PubMed 12908938
    126. PubMed 12908943
    127. PubMed 12908947
    128. PubMed 1353213
    129. PubMed 1355968
    130. PubMed 1364339
    131. PubMed 1417396
    132. PubMed 1430049
    133. PubMed 14499958
    134. PubMed 14586543
    135. PubMed 14640267
    136. PubMed 14643504
    137. PubMed 14670133
    138. PubMed 14979364
    139. PubMed 14987425
    140. PubMed 15053679
    141. PubMed 15062945
    142. PubMed 15103707
    143. PubMed 15116239
    144. PubMed 15228153
    145. PubMed 15516295
    146. PubMed 15634943
    147. PubMed 15712289
    148. PubMed 1574522
    149. PubMed 15806
    150. PubMed 15831439
    151. PubMed 15902982
    152. PubMed 15910012
    153. PubMed 15916245
    154. PubMed 15924321
    155. PubMed 15939177
    156. PubMed 15978345
    157. PubMed 16034267
    158. PubMed 16041709
    159. PubMed 16105252
    160. PubMed 16152661
    161. PubMed 16154523
    162. PubMed 16155817
    163. PubMed 16159994
    164. PubMed 16175411
    165. PubMed 16183702
    166. PubMed 16290021
    167. PubMed 16419398
    168. PubMed 16454462
    169. PubMed 16491100
    170. PubMed 16555062
    171. PubMed 16581972
    172. PubMed 1665919
    173. PubMed 16714155
    174. PubMed 16779783
    175. PubMed 16798115
    176. PubMed 17034801
    177. PubMed 17093959
    178. PubMed 17158196
    179. PubMed 17159795
    180. PubMed 17178092
    181. PubMed 17193269
    182. PubMed 1722593
    183. PubMed 1722755
    184. PubMed 1723801
    185. PubMed 17240388
    186. PubMed 1725282
    187. PubMed 17300894
    188. PubMed 17332148
    189. PubMed 17345065
    190. PubMed 17369000
    191. PubMed 17383132
    192. PubMed 17403620
    193. PubMed 17467183
    194. PubMed 17468860
    195. PubMed 17474080
    196. PubMed 17474141
    197. PubMed 17579960
    198. PubMed 17629643
    199. PubMed 17640955
    200. PubMed 17646137
    201. PubMed 17689300
    202. PubMed 1784586
    203. PubMed 17969820
    204. PubMed 1979813
    205. PubMed 1979827
    206. PubMed 1981721
    207. PubMed 2314063
    208. PubMed 239139
    209. PubMed 2443644
    210. PubMed 2446629
    211. PubMed 2457659
    212. PubMed 2472482
    213. PubMed 2569654
    214. PubMed 2576302
    215. PubMed 2760158
    216. PubMed 2871581
    217. PubMed 2875893
    218. PubMed 2880735
    219. PubMed 2881002
    220. PubMed 2881551
    221. PubMed 2883012
    222. PubMed 2886126
    223. PubMed 2896360
    224. PubMed 2901488
    225. PubMed 2908769
    226. PubMed 2975068
    227. PubMed 3215990
    228. PubMed 3285124
    229. PubMed 3436914
    230. PubMed 3699443
    231. PubMed 3753103
    232. PubMed 3769509
    233. PubMed 4414209
    234. PubMed 4443387
    235. PubMed 4575537
    236. PubMed 4669589
    237. PubMed 4679780
    238. PubMed 4715203
    239. PubMed 512617
    240. PubMed 513074
    241. PubMed 540488
    242. PubMed 5631047
    243. PubMed 590343
    244. PubMed 6102141
    245. PubMed 6147902
    246. PubMed 619124
    247. PubMed 6494215
    248. PubMed 6770411
    249. PubMed 7086839
    250. PubMed 7098452
    251. PubMed 7493075
    252. PubMed 7903993
    253. PubMed 7908887
    254. PubMed 8097107
    255. PubMed 8097718
    256. PubMed 8102882
    257. PubMed 8104465
    258. PubMed 8246240
    259. PubMed 8364510
    260. PubMed 8429622
    261. PubMed 8891915
    262. PubMed 9164561
    263. PubMed 9259001
    264. PubMed 9373962
    265. PubMed 9408221
    266. PubMed 9491966
    267. PubMed 9511861
    268. PubMed 9526575
    269. PubMed 9586861
    270. PubMed 9627975
    271. PubMed 9700554
    272. PubMed 972325
    273. PubMed 9869367
    274. PubMed 9891611
    275. Royal Society of Chemistry b010035h
    276. Royal Society of Chemistry b105321n
    277. Royal Society of Chemistry b200607c
    278. Royal Society of Chemistry b201496n
    279. Royal Society of Chemistry b310111h
    280. Royal Society of Chemistry b916368a
    281. Royal Society of Chemistry b917940b
    282. Royal Society of Chemistry b923184f
    283. Royal Society of Chemistry c002157a
    284. Royal Society of Chemistry c002558e
    285. Royal Society of Chemistry c0an00850h
    286. RSC Learn Chemistry Wiki 3,4-Methylenedioxyamphetamine
    287. Sigma-Aldrich CERILLIAN-M-012
    288. Sigma-Aldrich M-012
    289. Springer Nature Contribution of Cytochrome P450 2D6 to 3,4-Methylenedioxymethamphetamine Disposition in Humans
    290. The Merck Index Online cs000000011848
    291. Thieme Chemistry KD-16-0237
    292. Thomson Pharma 00059551
    293. Wikidata Q223020
    294. Wikipedia 3,4-Methylenedioxyamphetamine
    295. xPharm 8877

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.